Mammalian Target of Rapamycin Inhibitor-Associated Stomatitis in Hematopoietic Stem Cell Transplantation Patients Receiving Sirolimus Prophylaxis for Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 3, 2015, Pages 503-508

  Villa, Alessandro ^a   Aboalela, Ali ^a   Luskin, Katharine A ^b   Cutler, Corey S ^a   Sonis, Stephen T ^a   Woo, Sook Bin ^a   Peterson, Douglas E ^b   Treister, Nathaniel S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Graft versus host disease; Management; Sirolimus; Ulcers

Indexed keywords

ALUMINUM HYDROXIDE; BUDESONIDE; CLOBETASOL; DEXAMETHASONE; DIMETICONE; LIDOCAINE; MAGNESIUM HYDROXIDE; MOUTHWASH; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; TRIAMCINOLONE ACETONIDE; IMMUNOSUPPRESSIVE AGENT; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHEEK MUCOSA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL FEATURE; CONTINUOUS INFUSION; CORTICOSTEROID THERAPY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LOADING DRUG DOSE; MALE; MOUTH ULCER; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; PALLIATIVE THERAPY; REDUCED INTENSITY CONDITIONING; SOFT PALATE; STEROID THERAPY; STOMATITIS; TONGUE; TREATMENT OUTCOME; ALLOGRAFT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; CLINICAL TRIAL; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; RETROSPECTIVE STUDY; TIME;

ADULT; AGED; ALLOGRAFTS; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIROLIMUS; STOMATITIS; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84922827728     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2014.11.680     Document Type: Article

References (24)

1. Sehgal S.N. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003, 35:7S-14S.
2. Ali S.M., Sabatini D.M. Structure of S6 kinase 1 determines whether raptor-mTOR or rictor-mTOR phosphorylates its hydrophobic motif site. JBiol Chem 2005, 280:19445-19448.
3. Sarbassov D.D., Ali S.M., Kim D.H., et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004, 14:1296-1302.
4. Abouelnasr A., Roy J., Cohen S., et al. Defining the role of sirolimus in the management of graft-versus-host disease: from prophylaxis to treatment. Biol Blood Marrow Transplant 2013, 19:12-21.
5. Cutler C., Antin J.H. Sirolimus immunosuppression for graft-versus-host disease prophylaxis and therapy: an update. Curr Opin Hematol 2010, 17:500-504.
6. Battaglia M., Stabilini A., Roncarolo M.G. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-4748.
7. Johnson R.W. Sirolimus (Rapamune) in renal transplantation. Curr Opin Nephrol Hypertens 2002, 11:603-607.
8. Trotter J.F. Sirolimus in liver transplantation. Transplant Proc 2003, 35:193S-200S.
9. Machado P.G., Felipe C.R., Hanzawa N.M., et al. An open-label randomized trial of the safety and efficacy of sirolimus vs. azathioprine in living related renal allograft recipients receiving cyclosporine and prednisone combination. Clin Transplant 2004, 18:28-38.
10. Cutler C., Antin J.H. Sirolimus for GVHD prophylaxis in allogeneic stem cell transplantation. Bone Marrow Transplant 2004, 34:471-476.
11. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 2007, 109:3108-3114.
12. Cutler C., Logan B., Nakamura R., et al. Tacrolimus/sirolimus versus tacrolimus/methotrexate as GVHD prophylaxis after matched, related donor allogeneic hematopoietic cell transplantation. Blood 2014, 124:1372-1377.
13. Tenderich G., Fuchs U., Zittermann A., et al. Comparison of sirolimus and everolimus in their effects on blood lipid profiles and haematological parameters in heart transplant recipients. Clin Transplant 2007, 21:536-543.
14. Hong J.C., Kahan B.D. Sirolimus-induced thrombocytopenia and leukopenia in renal transplant recipients: risk factors, incidence, progression, and management. Transplantation 2000, 69:2085-2090.
15. Pham P.T., Pham P.C., Danovitch G.M., et al. Sirolimus-associated pulmonary toxicity. Transplantation 2004, 77:1215-1220.
16. Cutler C., Henry N.L., Magee C., et al. Sirolimus and thrombotic microangiopathy after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2005, 11:551-557.
17. Mahe E., Morelon E., Lechaton S., et al. Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy. Transplantation 2005, 79:476-482.
18. Sonis S., Treister N., Chawla S., et al. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients. Cancer 2010, 116:210-215.
19. MacDonald A.S. Aworldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients ofprimary mismatched renal allografts. Transplantation 2001, 71:271-280. Rapamune Global Study Group.
20. van Gelder T., ter Meulen C.G., Hene R., et al. Oral ulcers in kidney transplant recipients treated with sirolimus and mycophenolate mofetil. Transplantation 2003, 75:788-791.
21. Kahan B.D., Julian B.A., Pescovitz M.D., et al. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group. Transplantation 1999, 68:1526-1532.
22. de Oliveira M.A., Martins E.M.F., Wang Q., et al. Clinical presentation and management of mTOR inhibitor-associated stomatitis. Oral Oncol 2011, 47:998-1003.
23. Scully C. Clinical practice. Aphthous ulceration. NEngl J Med 2006, 355:165-172.
24. Kuten-Shorrer M., Woo S.B., Treister N.S. Oral graft-versus-host disease. Dent Clin North Am 2014, 58:351-368.